Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 12, 2008, Pages 3457-3466

  Chen, Chu ^a,b,c   Sakoda, Lori C ^a,b   Doherty, Jennifer A ^a   Loomis, Melissa M ^a   Fish, Sherianne ^a   Ray, Roberta M ^a   Ming, Gang Lin ^a   Fan, Wenhong ^a   Lue, Ping Zhao ^a,b   Dao, Li Gao ^d   Stalsberg, Helge ^e   Feng, Ziding ^a,b   Thomas, David B ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CHINA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROCYSTIC BREAST DISEASE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ALLELES; AROMATASE; BREAST NEOPLASMS; BREAST SELF-EXAMINATION; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHINA; FEMALE; FIBROCYSTIC BREAST DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 57449083997     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0517     Document Type: Article

References (56)

1. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982;42:3232-9.
2. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-8.
3. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
4. Bulun SE, Chen D, Lu M, et al. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 2007;106:81-96.
5. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;27:75-93.
6. Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri E. Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-α knock-out (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. Carcinogenesis 2001;22:1573-6.
7. Yue W, Santen RJ, Wang JP, et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003;86:477-86.
8. Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 1993;90:11312-6.
9. Mahendroo MS, Means GD, Mendelson CR, Simpson ER. Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. J Biol Chem 1991;266:11276-81.
10. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996;81:3843-9.
11. Utsumi T, Harada N, Maruta M, Takagi Y. Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. J Clin Endocrinol Metab 1996;81:2344-9.
12. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresendale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998;8:43-8.
13. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-63.
14. Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-93.
15. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-10.
16. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-8.
17. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-73.
18. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-9.
19. Miyoshi Y, Ando A, Hasegawa S, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39:2531-7.
20. Dialyna I, Tzanakakis G, Dolapsakis G, Tsatsakis A. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides. Toxicol Lett 2004;151:267-71.
21. Ahsan H, Whittemore AS, Chen Y, et al. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 2005;7:R71-81.
22. n polymorphism and breast cancer risk in Brazilian women. Toxicol Lett 2006;164:90-5.
23. Suspitsin EN, Grigoriev MY, Togo AV, et al. Distinct prevalence of the CYP19 Δ3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer 2002;38:1911-6.
24. Han DF, Zhou X, Hu MB, et al. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 2005;118:1507-16.
25. n polymorphism in CYP19 (aromatase) gene and breast cancer risk in Nigerian women. J Carcinog 2006;5:12.
26. Thyagarajan B, Brott M, Mink P, et al. CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC study. Cancer Lett 2004;207:183-9.
27. Olson JE, Ingle JN, Ma CX, et al. A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat 2007;102:237-47.
28. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-45.
29. Hefler LA, Tempfer CB, Grimm C, et al. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004;101:264-9.
30. Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004;13:1407-11.
31. Hu MB, Xie W, Xiong B, et al. Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:351-5.
32. Lee KM, Abel J, Ko Y, et al. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br J Cancer 2003;88:675-8.
33. Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19:1329-33.
34. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:215-6.
35. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-92.
36. Haiman CA, Dossus L, Setiawan VW, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels by not breast cancer risk in postmenopausal women. Cancer Res 2007;67:1893-7.
37. Cai Q, Kataoka N, Li C, et al. Haplotype Analyses of CYP19A1 Gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 2008;17:27-32.
38. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94-101.
39. Travis RC, Churchman M, Edwards SA, et al. No association of polymorphisms in CYP17, CYP19, and HSD17-1 with plasma estradiol concentrations in 1,090 British women. Cancer Epidemiol Biomarkers Prev 2004;13:2282-4.
40. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
41. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988;128:467-77.
42. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267:941-4.
43. Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 2005;116:267-74.
44. Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst 1997;89:355-65.
45. Thomas DB, Gao DL, Ray RM, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94:1445-57.
46. Sakoda LC, Blackston CR, Xue K, et al. Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women. Breast Cancer Res Treat 2008;109:143-55.
47. Aaman TB, Stalsberg H, Thomas DB; WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Extratumoral breast tissue in breast cancer patients: a multinational study of variations with age and country of residence in low- and high-risk countries. Int J Cancer 1997;71:333-9.
48. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
49. Suter NM, Ray RM, Hu YW, et al. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 2004;13:181-9.
50. Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5′ end of the human insulin gene. Proc Natl Acad Sci U S A 1981;78:5759-63.
51. Sinnwell JP, Schaid DJ, Yu Z. haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous. R package version 1.3.1. Available from: http://mayo/research.mayo.edu/mayo/research/ schaid_lab/software.cfm.
52. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L. Human aromatase: gene resequencing and functional genomics. Cancer Res 2005;65:11071-82.
53. Long JR, Kataoka N, Shu XO, et al. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 2006;15:2115-22.
54. Tao MH, Cai Q, Zhang ZF, et al. Polymorphisms in the CYP19A1 (aromatase) gene and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2007;16:943-9.
55. Long JR, Shu XO, Cai Q, et al. CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int J Obes 2007;31:418-23.
56. Rhiem K, Klein A, Munch M, et al. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003;106:74-7.